Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

NCT01907802 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

NIH

Sponsor class

Conditions

BRAF Gene Mutation
Hepatic Complication
Renal Failure
Solid Neoplasm

Interventions

DRUG: Dabrafenib
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacogenomic Study
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]